1689518D.S

Oculis announces publication and presentation of Phase 2 data showing topical OCS-01 improves macular thickness and visual acuity in patients with diabetic macular edema

Retrieved on: 
星期二, 九月 6, 2022
National, Diabetic retinopathy, CEO, Cerebral edema, Safety, Caregiver, Acta Ophthalmologica, Severe cognitive impairment, Doctor of Philosophy, Disease, Injection, DME, NIH, Reading, Quality of life, ACTA, MD, CMT, Retinal, Population, Edema, Universitate metro station, Dexamethasone, Diabetes, Data, Patient, Pharmaceutical industry, Ophthalmology, Massilia oculi

The publication is accessible on the National Institutes of Health (NIH) website here ( https://pubmed.ncbi.nlm.nih.gov/35848336/ ).

Key Points: 
  • The publication is accessible on the National Institutes of Health (NIH) website here ( https://pubmed.ncbi.nlm.nih.gov/35848336/ ).
  • Approximately 37 million people are affected by DME worldwide, representing around 7% of the large and growing diabetes patient population.
  • Although treatment options currently exist, all of them are invasive (injections or implants) and represent a significant burden for patients and caregivers.
  • With a presence in key international markets, Oculis is poised to deliver life-changing treatments to patients worldwide.

Oculis announces publication of Phase 2 data showing topical eye drops anti-TNFa agent licaminlimab (OCS-02) relieves persistent ocular discomfort in severe dry eye disease

Retrieved on: 
星期二, 八月 23, 2022
National, Inflammation, CEO, Tumor necrosis factor, Safety, Pain, Duane syndrome, Disease, Tissue, NIH, Clinical Ophthalmology (journal), DED, Hospital, Population, Fragment crystallizable region, Uveitis, Mall of America, MOA, Macular edema, POC, Quinze-Vingts National Ophthalmology Hospital, Patient, Pharmaceutical industry, Telescopic sight, Ophthalmology, Pecten oculi

Dry Eye is a multifactorial disease in which inflammation rapidly takes on a central role in sustaining the pathological state(1).

Key Points: 
  • Dry Eye is a multifactorial disease in which inflammation rapidly takes on a central role in sustaining the pathological state(1).
  • Licaminlimab (OCS-02) is currently being investigated by Oculis in Phase 2 clinical trials for the treatment of dry eye disease and uveitis.
  • I certainly look forward to the continued development and approval of OCS-02 in severe dry eye disease as these patients currently have limited treatment options."
  • EuDESEuropean Dry Eye Society https://www.dryeye-society.com/resources/dry-eye-disease-complex-interac...
    (2) Eric B Papas "The global prevalence of dry eye disease: A Bayesian view" 2021
    (5) Mukamal, R. Why is Dry Eye So Difficult to Treat?

Oculis Announces First Patient Enrolled in Phase 3 OPTIMIZE Trial of OCS-01 in the Treatment of Inflammation and Pain Following Cataract Surgery

Retrieved on: 
星期三, 六月 29, 2022
Trustee, Cataract, Retinal, Patient, Refractive surgery, CEO, Annual general meeting, DME, Ophthalmology, Retina, Disease, ASCRS, Pain, Inflammation, U.S. FDA, American Society of Cataract and Refractive Surgery, Dexamethasone, Minimisation, Safety, Society, Geisel School of Medicine, Pharmaceutical industry, Pecten oculi

In the completed Phase 2 SKYGGN study, once-daily OCS-01 successfully met its primary endpoint demonstrating superior efficacy and safety vs vehicle (placebo) in the treatment of inflammation and pain following cataract surgery.

Key Points: 
  • In the completed Phase 2 SKYGGN study, once-daily OCS-01 successfully met its primary endpoint demonstrating superior efficacy and safety vs vehicle (placebo) in the treatment of inflammation and pain following cataract surgery.
  • Positive data from that trial was presented at the American Society of Cataract and Refractive Surgery (ASCRS) 2020 Annual Meeting.
  • Oculis subsequently held a positive end-of-Phase 2 meeting with U.S. FDA which enabled the start of the Phase 3 OPTIMIZE trial.
  • Treatment of inflammation and pain following ocular surgery is another indication being pursued for OCS-01, following the commencement in November 2021 of the Phase 3 DIAMOND trial investigating OCS-01 in patients with DME.